Published in Am J Pathol on May 01, 1995
CD44 and the adhesion of neoplastic cells. Mol Pathol (1997) 1.12
Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem (1984) 18.48
CD44 is the principal cell surface receptor for hyaluronate. Cell (1990) 11.01
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell (1991) 7.29
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol (1990) 6.23
Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A (1992) 4.90
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer (1988) 4.03
Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol (1988) 3.84
Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol (1992) 3.41
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J Gen Virol (1987) 3.28
The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J (1991) 3.20
Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet (1992) 3.16
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (1990) 2.72
Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer (1988) 2.46
Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res (1994) 2.21
Expression and modulation of CD44 variant isoforms in humans. J Cell Biol (1994) 2.17
Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol (1992) 2.14
A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol (1993) 2.06
Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med (1993) 2.03
Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J Biol Chem (1992) 2.03
Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J Virol (1991) 1.91
Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol (1993) 1.88
Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med (1993) 1.77
Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res (1993) 1.68
Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res (1993) 1.68
Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J Cell Biol (1995) 1.65
P53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J Pathol (1993) 1.51
An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (1992) 1.33
The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res (1993) 1.28
Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am J Pathol (1992) 1.28
Alternative splicing of CD44 pre-mRNA in human colorectal tumors. Biochem Biophys Res Commun (1994) 1.18
Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol (1992) 1.09
Characterization of a 95,000 molecule on sheep leucocytes homologous to murine Pgp-1 and human CD44. Immunology (1988) 1.06
Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood (1993) 1.00
Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas. J Pathol (1994) 0.94
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Phosphorylation of initiation factor elF-2 and the control of reticulocyte protein synthesis. Cell (1977) 6.22
A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J (1988) 3.69
Accumulation of an mRNA and protein in interferon-treated Ehrlich ascites tumour cells. Nature (1979) 3.43
A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J Virol (1987) 3.10
Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J (1986) 3.07
The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol (1989) 2.98
Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood (1989) 2.95
Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95-8. J Virol (1985) 2.82
Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A (1991) 2.82
EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J (1994) 2.79
Transcription and DNA sequence of the BamHI L fragment of B95-8 Epstein-Barr virus. EMBO J (1984) 2.77
Epstein-Barr virus infection and replication in a human epithelial cell system. Nature (1992) 2.62
Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol (1991) 2.58
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med (1993) 2.56
Pathways of activation of the Epstein-Barr virus productive cycle. J Virol (1991) 2.42
Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4+ T-helper cells. Am J Pathol (1992) 2.37
Novel nuclear antigens recognized by human sera in lymphocytes latently infected by Epstein-Barr virus. Virology (1987) 2.32
The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene (1991) 2.25
Interferon action: two distinct pathways for inhibition of protein synthesis by double-stranded RNA. Proc Natl Acad Sci U S A (1978) 2.22
Homologous upstream sequences near Epstein-Barr virus promoters. Proc Natl Acad Sci U S A (1983) 1.98
Structure and function of the Epstein-Barr virus BZLF1 protein. J Virol (1990) 1.97
Sequence analysis of Raji Epstein-Barr virus DNA. Virology (1988) 1.95
Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer (2002) 1.95
Retracted Relation between infection with a subtype of HPV16 and cervical neoplasia. Lancet (1989) 1.94
Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region. Virology (1990) 1.78
The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol (2001) 1.73
Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol (1997) 1.72
Interferon, double-stranded RNA and RNA degradation. Fractionation of the endonucleaseINT system into two macromolecular components; role of a small molecule in nuclease activation. Biochem Biophys Res Commun (1978) 1.70
Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology (2011) 1.70
Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol (2000) 1.64
Mapping of the gene coding for Epstein-Barr virus-determined nuclear antigen EBNA3 and its transient overexpression in a human cell line by using an adenovirus expression vector. J Virol (1987) 1.61
Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol (1994) 1.60
Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol (1990) 1.60
The terminal protein gene 2 of Epstein-Barr virus is transcribed from a bidirectional latent promoter region. J Gen Virol (1989) 1.59
Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J Virol (2000) 1.57
Epstein-Barr virus/complement receptor and epithelial cells. Lancet (1989) 1.56
Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J Virol (1992) 1.55
The antibody 2B4 directed against the Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) detects MAGE-4: implications for studies on the EBV association of human cancers. J Pathol (2006) 1.55
High incidence of Epstein-Barr virus genomes in Hodgkin's disease. Am J Pathol (1990) 1.54
Analysis of phosphorylation of protein synthesis initiation factor eIF-2 by two-dimensional gel electrophoresis. Eur J Biochem (1978) 1.54
Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene (1996) 1.52
P53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J Pathol (1993) 1.51
Acquired resistance to Listeria monocytogenes is mediated by Lyt-2+ T cells independently of the influx of monocytes into granulomatous lesions. J Exp Med (1989) 1.50
Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol (1997) 1.49
Non-Hodgkin's lymphoma, coeliac disease, and Epstein-Barr virus: a study of 13 cases of enteropathy-associated T- and B-cell lymphoma. J Pathol (1995) 1.49
Sequences of the Epstein-Barr Virus (EBV) large internal repeat form the center of a 16-kilobase-pair palindrome of EBV (P3HR-1) heterogeneous DNA. J Virol (1987) 1.45
Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. Blood (1992) 1.45
The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol (1990) 1.44
Diving practices of scuba divers with asthma. BMJ (1990) 1.44
Epstein-Barr virus in inflammatory diseases of the liver and liver allografts: an in situ hybridization study. Hepatology (1994) 1.43
In situ detection of the Epstein-Barr virus-encoded nuclear antigen 1 in oral hairy leukoplakia and virus-associated carcinomas. J Pathol (1996) 1.43
The role of polyamines in cell-free protein synthesis in the wheat-germ system. Eur J Biochem (1977) 1.43
Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. J Virol (1996) 1.41
Retracted High rate of human papillomavirus type 16 infection in cytologically normal cervices. Lancet (1989) 1.38
Chromatin structure of Epstein-Barr virus. J Gen Virol (1985) 1.37
Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Invest (1993) 1.37
Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res (2001) 1.35
Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death. J Virol (2001) 1.34
DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J (1995) 1.33
Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood (1996) 1.32
DNA sequence analysis of the EcoRI Dhet fragment of B95-8 Epstein-Barr virus containing the terminal repeat sequences. Mol Biol Med (1983) 1.31
Prevalence of human papillomavirus type 16 DNA in cervical carcinoma samples in East Anglia. Int J Cancer (1985) 1.31
The association of squamous cell carcinomas of the nasopharynx with Epstein-Barr virus shows geographical variation reminiscent of Burkitt's lymphoma. J Pathol (1997) 1.30
Interferon, double-stranded RNA, and RNA degradation. Isolation of homogeneous pppA(2'p5'A)n-1 synthetase from Ehrlich ascites tumor cells. J Biol Chem (1980) 1.30
Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol (1996) 1.27
The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res (1996) 1.25
Unrearranged immunoglobulin variable region genes have a functional promoter. Nucleic Acids Res (1982) 1.23
Strain variation in Epstein-Barr virus immediate early genes. Virology (1993) 1.23
Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J (1995) 1.23
Abdominal actinomycosis: complication of endoscopic stenting in chronic pancreatitis? Endoscopy (2001) 1.23
Sequence analysis of the 17,166 base-pair EcoRI fragment C of B95-8 Epstein-Barr virus. Mol Biol Med (1983) 1.22
Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood (1996) 1.21
Epstein-Barr virus (EBV) in infectious mononucleosis: detection of the virus in tonsillar B lymphocytes but not in desquamated oropharyngeal epithelial cells. Mol Pathol (2000) 1.19
Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol (2007) 1.18
Epstein-Barr virus SM protein. Virology (1994) 1.18
Molecular genetic analysis of Epstein-Barr virus Cp promoter function. J Virol (1996) 1.16
Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood (1995) 1.15
Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res (2000) 1.14
Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. J Virol (1995) 1.12
RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene (2001) 1.12
Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B-cells. Oncogene (1996) 1.11
The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma. Ann Oncol (1991) 1.10
Cell growth effects of Epstein-Barr virus leader protein. J Gen Virol (1992) 1.09
Expression of cyclin D2 in Epstein-Barr virus-positive Burkitt's lymphoma cell lines is related to methylation status of the gene. J Virol (1995) 1.09
Epstein-Barr virus transcription factors. Cell Growth Differ (1992) 1.09
Extracts of interferon-treated cells can inhibit reticulocyte lysate protein synthesis. Biochem Biophys Res Commun (1977) 1.08
Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood (1999) 1.08
Multiple functions within the Epstein-Barr virus EBNA-3A protein. J Virol (1998) 1.05
Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection. J Virol (2001) 1.05
Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J Virol (1999) 1.04
A baculovirus (Bombyx mori nuclear polyhedrosis virus) repeat element functions as a powerful constitutive enhancer in transfected insect cells. J Biol Chem (1997) 1.03
Epstein-Barr virus and Burkitt lymphoma. Postgrad Med J (2008) 1.02
Novel hypotheses for the roles of EBNA-1 and BHRF1 in EBV-related cancers. Intervirology (1995) 1.02